Across TCGA pan-cancer cohorts, ANXA4 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ANXA4 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher ANXA4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANXA4 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

BRCA, PRAD, and BLCA are the cancer types where ANXA4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.107	0.578	.005	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BLCA	DFS	Median	III,IV	1.000	0.269	.035	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ANXA4 tumor-vs-normal RNA expression · all ANXA4 data types